Physiologically Based Pharmacokinetic Modelling-Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID-19 Treatment
COVID-19 patients with cardiovascular diseases who are at higher risk of progressing to critical illness should be treated with Paxlovid. Ritonavir, the booster in Paxlovid, modulates multiple drug metabolizing enzymes and transporters, complicating its use in real-world clinics. We aimed to apply physiologically based pharmacokinetic (PBPK) modelling to simulate the complex drug-drug interactions (DDIs) of ritonavir with two anticoagulants, rivaroxaban and racemic warfarin, to address this...